MedPage Today on MSN
Ulcerative Colitis: Next Target for CAR T-Cell Therapy?
The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...
For decades, diagnosis of brain cancer has been medicine’s most difficult and hazardous challenge. Simple imaging such as MRI ...
The transcription factor NF-κB is a key regulator of cell fate, extensively involved in various physiological and pathological processes such as ...
Breakthrough T1D (formerly JDRF), the Lupus Research Alliance, and the National Multiple Sclerosis Society today announce the ...
Vietnam Investment Review on MSN
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it ...
Findings offer hope for new treatments targeting inflammation-related conditions Two new studies from the lab of Steven E.
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy.
Scientists have engineered Salmonella bacteria to self-destruct inside tumors, releasing signals that spark powerful immune ...
Liver fibrosis, a pathological scarring process resulting from chronic liver injury, represents a significant global health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback